Agency Information Collection Activities; Proposed Collection; Comment Request; Veterinary Feed Directive, 2456-2459 [2018-00676]
Download as PDF
2456
Federal Register / Vol. 83, No. 11 / Wednesday, January 17, 2018 / Notices
TABLE 1—ANDAS FOR WHICH FDA IS WITHDRAWING APPROVAL—Continued
Application No.
Drug
Applicant
ANDA 075375 ..........
Diltiazem Hydrochloride (HCl) Injection, 5 mg/milliliter (mL)
ANDA 076911 ..........
Clorazepate Dipotassium Tablets USP, 3.75 mg, 7.5 mg,
and 15 mg.
ANDA 077102 ..........
Calcitriol Injection, 0.001 mg/mL ...........................................
ANDA 084656 ..........
Acetaminophen and Codeine Phosphate Tablets USP, 300
mg/30 mg.
Diphenhydramine HCl Capsules, 25 mg ..............................
Mylan Laboratories, Ltd., c/o Mylan Pharmaceuticals, Inc.,
781 Chestnut Ridge Rd., P.O. Box 4310, Morgantown,
WV 26504.
Sun Pharmaceutical Industries, Ltd., c/o Sun Pharmaceutical Industries, Inc., 2 Independence Way, Princeton,
NJ 08540.
Sagent Pharmaceuticals, Inc., 1901 N. Roselle Rd., Suite
450, Schaumburg, IL 60195.
Roxane Laboratories, Inc., 1809 Wilson Rd., Columbus,
OH 43228.
LNK International, Inc., 145 Ricefield Ln., Hauppauge, NY
11788.
LyphoMed, Division of Fujisawa USA, Inc., 2045 North
Cornell Ave., Melrose Park, IL 60160.
Purepac Pharmaceutical Co., 200 Elmora Ave., Elizabeth,
NJ 07207.
Superpharm Corp., 1769 Fifth Ave., Bayshore, NY 11706.
ANDA 087977 ..........
ANDA 088676 ..........
ANDA 089080 ..........
ANDA 089183 ..........
ANDA 089253 ..........
ANDA 089219 ..........
ANDA 089254 ..........
ANDA 089369 ..........
ANDA 089481 ..........
ANDA 089482 ..........
ANDA 089483 ..........
ANDA 206711 ..........
Methylprednisolone Sodium Succinate for Injection USP,
Equivalent to 40 mg base/vial.
Acetaminophen and Codeine Phosphate Tablets USP, 300
mg/30 mg.
Acetaminophen and Codeine Phosphate Tablets USP, 300
mg/15 mg.
Acetaminophen and Codeine Phosphate Tablets USP, 300
mg/30 mg.
Procainamide HCl Capsules USP, 250 mg, 375 mg, and
500 mg.
Acetaminophen and Codeine Phosphate Tablets USP, 300
mg/60 mg.
Procainamide HCl Extended-Release Tablets USP, 250
mg, 500 mg, and 750 mg.
Acetaminophen and Codeine Phosphate Tablets USP, 300
mg/15 mg.
Acetaminophen and Codeine Phosphate Tablets USP, 300
mg/30 mg.
Acetaminophen and Codeine Phosphate Tablets USP, 300
mg/60 mg.
Olanzapine Tablets USP, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15
mg, and 20 mg.
ethrower on DSK3G9T082PROD with NOTICES
Therefore, approval of the
applications listed in table 1, and all
amendments and supplements thereto,
is hereby withdrawn as of February 16,
2018. Introduction or delivery for
introduction into interstate commerce of
products without approved new drug
applications violates section 301(a) and
(d) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 331(a) and (d)).
Drug products that are listed in table 1
that are in inventory on the date that
this notice becomes effective (see the
DATES section) may continue to be
dispensed until the inventories have
been depleted or the drug products have
reached their expiration dates or
otherwise become violative, whichever
occurs first.
Dated: January 11, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018–00695 Filed 1–16–18; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
17:14 Jan 16, 2018
Jkt 244001
Do.
IDT Australia, Ltd., c/o Facet Life Sciences, Inc., 6122
Stone Wolfe Dr., Glen Carbon, IL 62034.
Do.
Do.
American Therapeutics, Inc., 75 Carlough Rd., Bohemia,
NY 11716.
Do.
Do.
Ajanta Pharma, Ltd., c/o Ajanta Pharma USA, Inc., One
Grande Commons, 440 U.S. Highway 22 East, Suite
150, Bridgewater, NJ 08807.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0155]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Veterinary Feed
Directive
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA, Agency or we) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information, and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on the information
SUMMARY:
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
collection provisions of our veterinary
feed directive (VFD) regulation.
DATES: Submit either electronic or
written comments on the collection of
information by March 19, 2018.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before March 19,
2018. The https://www.regulations.gov
electronic filing system will accept
comments until midnight Eastern Time
at the end of March 19, 2018. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are
postmarked or the delivery service
acceptance receipt is on or before that
date.
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
E:\FR\FM\17JAN1.SGM
17JAN1
Federal Register / Vol. 83, No. 11 / Wednesday, January 17, 2018 / Notices
ethrower on DSK3G9T082PROD with NOTICES
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2010–N–0155 for ‘‘Agency Information
Collection Activities; Proposed
Collection; Comment Request;
Veterinary Feed Directive.’’ Received
comments, those filed in a timely
manner (see ADDRESSES), will be placed
in the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff office
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
VerDate Sep<11>2014
17:14 Jan 16, 2018
Jkt 244001
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Ila
S. Mizrachi, Office of Operations, Food
and Drug Administration, Three White
Flint North, 10A–12M, 11601
Landsdown St., North Bethesda, MD
20852, 301–796–7726, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
2457
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Veterinary Feed Directive—21 CFR
558.6
OMB Control Number 0910–0363—
Extension
Section 504 of the Federal Food, Drug,
and Cosmetic Act (the FD&C Act) (21
U.S.C. 354) establishes a regulatory
category for certain new animal drugs
called VFD drugs. Our VFD regulation is
set forth at § 558.6 (21 CFR 558.6). VFD
drugs are new animal drugs intended for
use in or on animal feed which are
limited to use under the professional
supervision of a licensed veterinarian in
the course of the veterinarian’s
professional practice (§ 558.3 (21 CFR
558.3(b)(6))). An animal feed containing
a VFD drug or a combination VFD drug
may be fed to animals only by or upon
a lawful VFD issued by a licensed
veterinarian (§ 558.6(a)(1)).
Veterinarians issue three copies of the
VFD: one for their own records, one for
their client, and one to the client’s VFD
feed distributor (§§ 558.6(a)(4) and
558.6(b)(8)–(9)). The VFD includes
information about the number and
species of animals to receive feed
containing one or more of the VFD
drugs (§ 558.6(b)(3)), along with other
information required under § 558.6. All
distributors of medicated feed
containing VFD drugs must notify us of
their intent to distribute such feed and
must maintain records of the receipt and
distribution of all medicated feeds
containing VFD drugs.
The VFD regulation ensures the
protection of public health while
enabling animal producers to obtain and
use needed drugs as efficiently and costeffectively as possible. The VFD
regulation is tailored to the unique
circumstances relating to the
distribution and use of animal feeds
containing a VFD drug.
We will use the information collected
to assess compliance with the VFD
regulation. The required recordkeeping
and third party disclosures provide
assurance that the medicated feeds will
be safe and effective for their labeled
conditions of use and that edible
E:\FR\FM\17JAN1.SGM
17JAN1
2458
Federal Register / Vol. 83, No. 11 / Wednesday, January 17, 2018 / Notices
products from treated animals will be
free of unsafe drug residues.
We estimate the burden of this
collection of information as follows. We
base our estimates on our analysis of the
information collection provisions of the
final rule entitled ‘‘Veterinary Feed
Directive,’’ published in the Federal
Register of June 3, 2015 (80 FR 31708
at 31728) (the June 3, 2015, final rule).
within 30 days of any change in
ownership, business name, or business
address (§ 558.6(c)(6)). Additional
reporting burdens for current VFD drug
sponsors are approved under OMB
control numbers 0910–0032 (New
Animal Drug Applications) and 0910–
0669 (Abbreviated New Animal Drug
Applications).
FDA estimates the burden of this
collection of information as follows:
A. Reporting Requirements
Description of Respondents: VFD
Feed Distributors, VFD Drug Sponsors.
A distributor of animal feed
containing a VFD drug must notify us
prior to the first time it distributes the
VFD feed (§ 558.6(c)(5)). This
notification is required one time per
distributor and must include the
information set forth in § 558.6(c)(5). In
addition, a distributor must notify us
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
responses
per
respondent
Number of
respondents
21 CFR section, activity
Total annual
responses
Average burden per response
Total hours
558.6(c)(5); requires a distributor to
notify us prior to the first time it
distributes a VFD feed.
558.6(c)(6); requires a distributor to
notify us within 30 days of any
change in ownership, business
name, or business address.
300
1
300
.125 (7 minutes) ...............................
37.5
20
1
20
.125 (7 minutes) ...............................
2.5
Total ...........................................
........................
........................
........................
...........................................................
40
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
B. Recordkeeping Requirements
Description of Respondents: VFD
Feed Distributors, Food Animal
Veterinarians, and Clients (Food Animal
Producers).
As stated previously, veterinarians
issue three copies of the VFD: One for
their own records, one for their client,
and one to the client’s VFD feed
distributor. All involved parties (the
veterinarian, the distributor, and the
client) must retain a copy of the VFD for
2 years (§ 558.6(a)(4)). In addition, VFD
feed distributors must also keep receipt
and distribution records of VFD feeds
they manufacture and make them
available for inspection by us for 2 years
(§ 558.6(c)(3)).
If a distributor manufactures the VFD
feed, the distributor must also keep VFD
manufacturing records for 1 year in
accordance with 21 CFR part 225 and
such records must be made available for
inspection and copying by FDA upon
request (§ 558.6(c)(4)). These record
requirements are currently approved
under OMB control number 0910–0152,
‘‘Current Good Manufacturing Practice
Regulations for Medicated Feed.’’
Distributors may distribute VFD to
another distributor only if the
originating distributor first obtains a
written acknowledgement letter. Such
letters, like VFDs, are also subject to a
2-year record retention requirement
(§ 558.6(c)(8)).
TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1
Number of
recordkeepers
21 CFR section, activity
Number of
records per
recordkeeper
Total annual
records
Average burden per recordkeeping
Total hours
558.6(a)(4); required recordkeeping
by veterinarians and producers.
558.6(a)(4), (c)(3)–(4), and (c)(8); required recordkeeping by distributors.
13,050
114.9
1,500,000
.0167 (1 minute) ...............................
25,050
1,376
545.1
750,000
.0167 (1 minute) ...............................
12,525
Total ...........................................
........................
........................
........................
...........................................................
37,575
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
ethrower on DSK3G9T082PROD with NOTICES
C. Third-Party Disclosure Requirements
Description of Respondents: VFD
Drug Sponsors, Food Animal
Veterinarians, VFD Feed Distributors,
and Clients.
VerDate Sep<11>2014
17:14 Jan 16, 2018
Jkt 244001
Our regulation requires that
veterinarians include the information
specified at § 558.6(b)(3) through (5) on
the VFD. Additional requirements
relating to the VFD are specified at
§ 558.6(b)(7) through (9). A distributor
may only distribute a VFD feed to
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
another distributor for further
distribution if the originating distributor
(consignor) first obtains a written
acknowledgement letter from the
receiving distributor (consignee) before
the feed is shipped (§ 558.6(c)(8)).
E:\FR\FM\17JAN1.SGM
17JAN1
Federal Register / Vol. 83, No. 11 / Wednesday, January 17, 2018 / Notices
2459
TABLE 3—ESTIMATED ANNUAL THIRD-PARTY DISCLOSURE BURDEN 1
Number of
disclosures
per
respondent
Number of
respondents
21 CFR section, activity
Total annual
disclosures
Average burden per disclosure
Total hours
558.6(b)(3)–(5) and (b)(7)-(9); required disclosures when a veterinarian issues a VFD.
558.6(c)(8); required disclosure (acknowledgement letter) from one
distributor to another.
3,050
246
750,000
.125 (7 minutes) ...............................
93,750
1,000
5
5,000
.125 (7 minutes) ...............................
625
Total ...........................................
........................
........................
........................
...........................................................
94,375
ethrower on DSK3G9T082PROD with NOTICES
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
The VFD regulation also contains
several labeling provisions that are
exempt from OMB review and approval
under the PRA because they are a
‘‘public disclosure of information
originally supplied by the Federal
government to the recipient for the
purpose of disclosure to the public’’ (5
CFR 1320.3(c)(2)) and therefore do not
constitute a ‘‘collection of information’’
under the PRA (44 U.S.C. 3501, et seq.).
All labeling and advertising for VFD
drugs, combination VFD drugs, and
feeds containing VFD drugs or
combination VFD drugs must
prominently and conspicuously display
the following cautionary statement:
‘‘Caution: Federal law restricts
medicated feed containing this
veterinary feed directive (VFD) drug to
use by or on the order of a licensed
veterinarian’’ (§ 558.6(a)(6)). In addition,
the veterinarian must ensure that the
following statement is included on the
VFD (§ 558.6(b)(3)(xiii)): ‘‘Use of feed
containing this veterinary feed directive
(VFD) drug in a manner other than as
directed on the labeling (extralabel use)
is not permitted.’’
The veterinarian may restrict VFD
authorization to only include the VFD
drug(s) cited on the VFD or such
authorization may be expanded to allow
the use of the cited VFD drug(s) along
with one or more over-the-counter
animal drugs in an approved,
conditionally approved, or indexed
combination VFD drug (§ 558.6(b)(6)).
The veterinarian must affirm his or her
intent regarding combination VFD drugs
by including one of the following
statements on the VFD:
1. ‘‘This VFD only authorizes the use
of the VFD drug(s) cited in this order
and is not intended to authorize the use
of such drug(s) in combination with any
other animal drugs’’ (§ 558.6(b)(6)(i)).
2. ‘‘This VFD authorizes the use of the
VFD drug(s) cited in this order in the
following FDA-approved, conditionally
approved, or indexed combination(s) in
medicated feed that contains the VFD
VerDate Sep<11>2014
17:14 Jan 16, 2018
Jkt 244001
drug(s) as a component.’’ (List specific
approved, conditionally approved, or
indexed combination medicated feeds
following this statement.
§ 558.6(b)(6)(ii).)
3. ‘‘This VFD authorizes the use of the
VFD drug(s) cited in this order in any
FDA-approved, conditionally approved,
or indexed combination(s) in medicated
feed that contains the VFD drug(s) as a
component’’ (§ 558.6(b)(6)(iii)).
These labeling statements are not
subject to review by OMB because, as
stated previously, they are a ‘‘public
disclosure of information originally
supplied by the Federal government to
the recipient for the purpose of
disclosure to the public’’ (5 CFR
1320.3(c)(2)) and therefore do not
constitute a ‘‘collection of information’’
under the PRA (44 U.S.C. 3501, et seq.).
Our estimate of the annual burden for
this information collection has not
changed since the last OMB approval,
which was associated with the June 3,
2015, final rule. However, the one-time
burdens that we included in our
analysis of the June 3, 2015, final rule
(80 FR 31708 at 31729 to 31732) are not
included in our current estimate.
Dated: January 11, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018–00676 Filed 1–16–18; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–E–3619]
Food and Drug Administration,
HHS.
ACTION:
PO 00000
Notice.
Frm 00038
Fmt 4703
Sfmt 4703
Anyone with knowledge that any
of the dates as published (in the
SUPPLEMENTARY INFORMATION section) are
incorrect may submit either electronic
or written comments and ask for a
redetermination by March 19, 2018.
Furthermore, any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period by
July 16, 2018. See ‘‘Petitions’’ in the
SUPPLEMENTARY INFORMATION section for
more information.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before March 19,
2018. The https://www.regulations.gov
electronic filing system will accept
comments until midnight Eastern Time
at the end of March 19, 2018. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are
postmarked or the delivery service
acceptance receipt is on or before that
date.
DATES:
Electronic Submissions
Determination of Regulatory Review
Period for Purposes of Patent
Extension; AXUMIN
AGENCY:
The Food and Drug
Administration (FDA or the Agency) has
determined the regulatory review period
for AXUMIN and is publishing this
notice of that determination as required
by law. FDA has made the
determination because of the
submission of an application to the
Director of the U.S. Patent and
Trademark Office (USPTO), Department
of Commerce, for the extension of a
patent which claims that human drug
product.
SUMMARY:
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
E:\FR\FM\17JAN1.SGM
17JAN1
Agencies
[Federal Register Volume 83, Number 11 (Wednesday, January 17, 2018)]
[Notices]
[Pages 2456-2459]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-00676]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0155]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Veterinary Feed Directive
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA, Agency or we) is
announcing an opportunity for public comment on the proposed collection
of certain information by the Agency. Under the Paperwork Reduction Act
of 1995 (PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on the information collection
provisions of our veterinary feed directive (VFD) regulation.
DATES: Submit either electronic or written comments on the collection
of information by March 19, 2018.
ADDRESSES: You may submit comments as follows. Please note that late,
untimely filed comments will not be considered. Electronic comments
must be submitted on or before March 19, 2018. The https://www.regulations.gov electronic filing system will accept comments until
midnight Eastern Time at the end of March 19, 2018. Comments received
by mail/hand delivery/courier (for written/paper submissions) will be
considered timely if they are postmarked or the delivery service
acceptance receipt is on or before that date.
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to
[[Page 2457]]
the docket unchanged. Because your comment will be made public, you are
solely responsible for ensuring that your comment does not include any
confidential information that you or a third party may not wish to be
posted, such as medical information, your or anyone else's Social
Security number, or confidential business information, such as a
manufacturing process. Please note that if you include your name,
contact information, or other information that identifies you in the
body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2010-N-0155 for ``Agency Information Collection Activities;
Proposed Collection; Comment Request; Veterinary Feed Directive.''
Received comments, those filed in a timely manner (see ADDRESSES), will
be placed in the docket and, except for those submitted as
``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff office between 9
a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Ila S. Mizrachi, Office of Operations,
Food and Drug Administration, Three White Flint North, 10A-12M, 11601
Landsdown St., North Bethesda, MD 20852, 301-796-7726,
[email protected].
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Veterinary Feed Directive--21 CFR 558.6
OMB Control Number 0910-0363--Extension
Section 504 of the Federal Food, Drug, and Cosmetic Act (the FD&C
Act) (21 U.S.C. 354) establishes a regulatory category for certain new
animal drugs called VFD drugs. Our VFD regulation is set forth at Sec.
558.6 (21 CFR 558.6). VFD drugs are new animal drugs intended for use
in or on animal feed which are limited to use under the professional
supervision of a licensed veterinarian in the course of the
veterinarian's professional practice (Sec. 558.3 (21 CFR
558.3(b)(6))). An animal feed containing a VFD drug or a combination
VFD drug may be fed to animals only by or upon a lawful VFD issued by a
licensed veterinarian (Sec. 558.6(a)(1)).
Veterinarians issue three copies of the VFD: one for their own
records, one for their client, and one to the client's VFD feed
distributor (Sec. Sec. 558.6(a)(4) and 558.6(b)(8)-(9)). The VFD
includes information about the number and species of animals to receive
feed containing one or more of the VFD drugs (Sec. 558.6(b)(3)), along
with other information required under Sec. 558.6. All distributors of
medicated feed containing VFD drugs must notify us of their intent to
distribute such feed and must maintain records of the receipt and
distribution of all medicated feeds containing VFD drugs.
The VFD regulation ensures the protection of public health while
enabling animal producers to obtain and use needed drugs as efficiently
and cost-effectively as possible. The VFD regulation is tailored to the
unique circumstances relating to the distribution and use of animal
feeds containing a VFD drug.
We will use the information collected to assess compliance with the
VFD regulation. The required recordkeeping and third party disclosures
provide assurance that the medicated feeds will be safe and effective
for their labeled conditions of use and that edible
[[Page 2458]]
products from treated animals will be free of unsafe drug residues.
We estimate the burden of this collection of information as
follows. We base our estimates on our analysis of the information
collection provisions of the final rule entitled ``Veterinary Feed
Directive,'' published in the Federal Register of June 3, 2015 (80 FR
31708 at 31728) (the June 3, 2015, final rule).
A. Reporting Requirements
Description of Respondents: VFD Feed Distributors, VFD Drug
Sponsors.
A distributor of animal feed containing a VFD drug must notify us
prior to the first time it distributes the VFD feed (Sec.
558.6(c)(5)). This notification is required one time per distributor
and must include the information set forth in Sec. 558.6(c)(5). In
addition, a distributor must notify us within 30 days of any change in
ownership, business name, or business address (Sec. 558.6(c)(6)).
Additional reporting burdens for current VFD drug sponsors are approved
under OMB control numbers 0910-0032 (New Animal Drug Applications) and
0910-0669 (Abbreviated New Animal Drug Applications).
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of
21 CFR section, activity Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
----------------------------------------------------------------------------------------------------------------
558.6(c)(5); requires a 300 1 300 .125 (7 minutes) 37.5
distributor to notify us
prior to the first time it
distributes a VFD feed.
558.6(c)(6); requires a 20 1 20 .125 (7 minutes) 2.5
distributor to notify us
within 30 days of any change
in ownership, business name,
or business address.
---------------
Total..................... .............. .............. .............. ................ 40
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
B. Recordkeeping Requirements
Description of Respondents: VFD Feed Distributors, Food Animal
Veterinarians, and Clients (Food Animal Producers).
As stated previously, veterinarians issue three copies of the VFD:
One for their own records, one for their client, and one to the
client's VFD feed distributor. All involved parties (the veterinarian,
the distributor, and the client) must retain a copy of the VFD for 2
years (Sec. 558.6(a)(4)). In addition, VFD feed distributors must also
keep receipt and distribution records of VFD feeds they manufacture and
make them available for inspection by us for 2 years (Sec.
558.6(c)(3)).
If a distributor manufactures the VFD feed, the distributor must
also keep VFD manufacturing records for 1 year in accordance with 21
CFR part 225 and such records must be made available for inspection and
copying by FDA upon request (Sec. 558.6(c)(4)). These record
requirements are currently approved under OMB control number 0910-0152,
``Current Good Manufacturing Practice Regulations for Medicated Feed.''
Distributors may distribute VFD to another distributor only if the
originating distributor first obtains a written acknowledgement letter.
Such letters, like VFDs, are also subject to a 2-year record retention
requirement (Sec. 558.6(c)(8)).
Table 2--Estimated Annual Recordkeeping Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of Average burden
21 CFR section, activity Number of records per Total annual per Total hours
recordkeepers recordkeeper records recordkeeping
----------------------------------------------------------------------------------------------------------------
558.6(a)(4); required 13,050 114.9 1,500,000 .0167 (1 minute) 25,050
recordkeeping by
veterinarians and producers.
558.6(a)(4), (c)(3)-(4), and 1,376 545.1 750,000 .0167 (1 minute) 12,525
(c)(8); required
recordkeeping by distributors.
---------------
Total..................... .............. .............. .............. ................ 37,575
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
C. Third-Party Disclosure Requirements
Description of Respondents: VFD Drug Sponsors, Food Animal
Veterinarians, VFD Feed Distributors, and Clients.
Our regulation requires that veterinarians include the information
specified at Sec. 558.6(b)(3) through (5) on the VFD. Additional
requirements relating to the VFD are specified at Sec. 558.6(b)(7)
through (9). A distributor may only distribute a VFD feed to another
distributor for further distribution if the originating distributor
(consignor) first obtains a written acknowledgement letter from the
receiving distributor (consignee) before the feed is shipped (Sec.
558.6(c)(8)).
[[Page 2459]]
Table 3--Estimated Annual Third-Party Disclosure Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of
Number of disclosures Total annual Average burden
21 CFR section, activity respondents per disclosures per disclosure Total hours
respondent
----------------------------------------------------------------------------------------------------------------
558.6(b)(3)-(5) and (b)(7)- 3,050 246 750,000 .125 (7 minutes) 93,750
(9); required disclosures
when a veterinarian issues a
VFD.
558.6(c)(8); required 1,000 5 5,000 .125 (7 minutes) 625
disclosure (acknowledgement
letter) from one distributor
to another.
---------------
Total..................... .............. .............. .............. ................ 94,375
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
The VFD regulation also contains several labeling provisions that
are exempt from OMB review and approval under the PRA because they are
a ``public disclosure of information originally supplied by the Federal
government to the recipient for the purpose of disclosure to the
public'' (5 CFR 1320.3(c)(2)) and therefore do not constitute a
``collection of information'' under the PRA (44 U.S.C. 3501, et seq.).
All labeling and advertising for VFD drugs, combination VFD drugs, and
feeds containing VFD drugs or combination VFD drugs must prominently
and conspicuously display the following cautionary statement:
``Caution: Federal law restricts medicated feed containing this
veterinary feed directive (VFD) drug to use by or on the order of a
licensed veterinarian'' (Sec. 558.6(a)(6)). In addition, the
veterinarian must ensure that the following statement is included on
the VFD (Sec. 558.6(b)(3)(xiii)): ``Use of feed containing this
veterinary feed directive (VFD) drug in a manner other than as directed
on the labeling (extralabel use) is not permitted.''
The veterinarian may restrict VFD authorization to only include the
VFD drug(s) cited on the VFD or such authorization may be expanded to
allow the use of the cited VFD drug(s) along with one or more over-the-
counter animal drugs in an approved, conditionally approved, or indexed
combination VFD drug (Sec. 558.6(b)(6)). The veterinarian must affirm
his or her intent regarding combination VFD drugs by including one of
the following statements on the VFD:
1. ``This VFD only authorizes the use of the VFD drug(s) cited in
this order and is not intended to authorize the use of such drug(s) in
combination with any other animal drugs'' (Sec. 558.6(b)(6)(i)).
2. ``This VFD authorizes the use of the VFD drug(s) cited in this
order in the following FDA-approved, conditionally approved, or indexed
combination(s) in medicated feed that contains the VFD drug(s) as a
component.'' (List specific approved, conditionally approved, or
indexed combination medicated feeds following this statement. Sec.
558.6(b)(6)(ii).)
3. ``This VFD authorizes the use of the VFD drug(s) cited in this
order in any FDA-approved, conditionally approved, or indexed
combination(s) in medicated feed that contains the VFD drug(s) as a
component'' (Sec. 558.6(b)(6)(iii)).
These labeling statements are not subject to review by OMB because,
as stated previously, they are a ``public disclosure of information
originally supplied by the Federal government to the recipient for the
purpose of disclosure to the public'' (5 CFR 1320.3(c)(2)) and
therefore do not constitute a ``collection of information'' under the
PRA (44 U.S.C. 3501, et seq.). Our estimate of the annual burden for
this information collection has not changed since the last OMB
approval, which was associated with the June 3, 2015, final rule.
However, the one-time burdens that we included in our analysis of the
June 3, 2015, final rule (80 FR 31708 at 31729 to 31732) are not
included in our current estimate.
Dated: January 11, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018-00676 Filed 1-16-18; 8:45 am]
BILLING CODE 4164-01-P